In this edition of Anaesthesia and Intensive Care, Fowler and Christelis present an opinion article 1 that tantalisingly poses a question as its title: ''High volume local infiltration analgesia (HVLIA) compared to peripheral nerve block for hip and knee arthroplasty-what is the evidence?" The answer is, 'not much.' They cite two randomised trials 2, 3 for total knee arthroplasty with 20 patients in each treatment arm. The two different trials used different techniques and drew opposite conclusions based on patient controlled intravenous morphine consumption. They were not powered to draw any other conclusions. Additionally, a prospective, crossover, randomised trial 4 with 16 patients in each treatment arm was unable to detect a difference in morphine consumption. In total hip arthroplasty the evidence is even thinner and the final sentence of the abstract heralds the all too familiar refrain: "Well designed trials directly comparing peripheral nerve block with a standardised HVLIA technique are urgently required".
Following Kerr and Kohan's case series, published in 2008 5 , HVLIA has become widely practised for hip and knee arthroplasty. HVLIA is very seductive for the surgeon, anaesthetist and non-specialised postoperative care settings. It is simple, fast, usually results in no motor block and (if it works) can require less postoperative nursing skills than peripheral nerve blocks with local anaesthetic infusions down a catheter. The elephant in the room is that we are not comfortable with our own feelings of whether or not it works well enough and is good for our patients. These feelings are well founded. The exclusion criteria for those trials severely limit their generalisability to the arthroplasty-requiring population (no obese or opioid-tolerant patients), the primary outcomes are irrelevant to our patients and their capacity to detect differences between groups for relevant outcomes such as acute pain, success of the prosthesis, functional outcomes and persistent pain is currently unknown. The assumption that 'no statistically significant difference found between these techniques for relevant outcomes in arthroplasty means that there is no difference' is incorrect, as the existing trials have not been powered to find these differences. It therefore follows that we should not just take the easy route in our practice due to lack of conclusive outcomes; we just haven't looked adequately.
It is within this milieu that uncomfortable negotiations have been occurring between orthopaedic surgeons and anaesthetists. Embedded within these negotiations are complex professional selfesteem, patient and system issues. These need to be acknowledged openly if appropriate postoperative analgesic and system choices are to be made. Issues for individual negotiation include: whom should we be referring to a pain clinic prior to considering arthroplasty; and which patients should receive which local anaesthetic technique and why. It is extremely unlikely that one technique is best for all patients so flexibility and agreement is required. What is an acceptable failure rate of the primary analgesic plan? What is the rescue plan and how will it be instituted? What analgesic plan do we have in addition to local anaesthetic injected somewhere? In what institutions will we, or won't we perform arthroplasty? Which patients need to be admitted to which institution? Is a pain service mandatory? How are we involving the paramedical stakeholders to optimise patient outcomes? How do we detect and manage analgesic-related problems and complications?
These are the big-ticket items in anaesthesia for arthroplasty that need to be addressed. It is only when your arthroplasty team are on the same page and heading in the same direction that evidence for relevant outcomes may emerge. Fowler and Christelis conclude their article with some excellent advice:
Whatever technique is chosen, a multimodal, multidisciplinary approach should be employed, ideally in the setting of a comprehensive enhanced recovery after surgery program or similar protocol.
In the interim we can probably expect more data published concerning an ungeneralisable population of arthroplasty patients, powered to detect an uninformative 30 to 40% difference in morphine consumption and an unknown capacity to exclude differences in meaningful outcomes. The answer to the simple question of whether patients are better off with HVLIA or peripheral nerve block (or combinations of both) has not been answered. I Editorial The easy option? 
